Expertise in
9
conditions

Anne Banos

Bayonne, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
Bayonne, FR 

Overview

Anne Banos practices practicing medicine in Bayonne, France.

Ms. Banos is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Myelodysplastic Syndrome (MDS), Leukemia, and Non-Hodgkin Lymphoma.

She is actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 18 clinical trials.

Gender

Female

Locations

Bayonne, France
Other Locations
Hôpital St Louis, APHP
Paris, France
CHU Bordeaux
Pessac-sur-dordogne, France
Biarritz, France
Nantes, France
Clermont-ferrand, France
Metz, France
France
Poitiers, France
CHU de Dijon
Dijon, France
Lens, France
Perigueux, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Enrollment Status: Recruiting
Publish Date: March 05, 2026
Intervention Type: Drug
Study Drugs: Luspatercept, Eprex
Study Phase: Phase 1/Phase 2
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Carfilzomib
Study Phase: Phase 2
A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 2
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Enrollment Status: Completed
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: AG-221 IDH2 Inhibitor
Study Phase: Phase 2
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: AG-120
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drug: EPREX Erythropoietin
Study Phase: Phase 3
Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Methotrexate, Cyclophosphamide
Study Phase: Phase 2
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
View 9 Less Clinical Trials

43 Total Publications

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.
Journal: Blood advances
Published: January 02, 2025

Frequently Asked Questions about Anne Banos

Is Anne Banos a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Anne Banos is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anne Banos participate in research or clinical trials?

Yes. Anne Banos has published 43 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Anne Banos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Banos's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile